The POMT2 gene plays a crucial role in the development and function of muscles and the brain. Mutations in this gene can lead to a form of muscular dystrophy-dystroglycanopathy, specifically categorized as Congenital with Brain and Eye Anomalies Type A2 (MDDGA2). This condition is characterized by muscle weakness, developmental delays, and abnormalities in the brain and eyes from birth. Genetic testing for mutations in the POMT2 gene is essential for diagnosing this disorder, enabling early intervention and management of symptoms.
DNA Labs UAE offers a comprehensive genetic test to identify mutations in the POMT2 gene, providing crucial information for affected families. The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory. Results from this test can help in confirming the diagnosis, understanding the severity of the condition, and informing treatment options. It also aids in genetic counseling, offering families insights into the risk of the condition recurring in future pregnancies.
The POMGNT2 Gene Muscular Dystrophy-Dystroglycanopathy Congenital with Brain and Eye Anomalies Type A8 genetic test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the POMGNT2 gene. This gene plays a crucial role in the proper development and functioning of muscles, the brain, and eyes. Mutations in POMGNT2 can lead to a rare form of muscular dystrophy-dystroglycanopathy, which is characterized by congenital muscular dystrophy coupled with brain and eye anomalies, classified as Type A8.
This genetic test is essential for the early detection and diagnosis of this condition, enabling healthcare providers to develop a tailored management and treatment plan for affected individuals. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for any genetic abnormalities associated with the condition.
The cost of the POMGNT2 Gene Muscular Dystrophy-Dystroglycanopathy Congenital with Brain and Eye Anomalies Type A8 genetic test at DNA Labs UAE is 4400 AED. Given the complexity and specificity of this test, it represents a crucial investment in the health and well-being of individuals at risk of or suspected to have this rare disorder. Early diagnosis through genetic testing can significantly impact the quality of life, allowing for timely interventions and support for those affected and their families.
The POMT2 gene muscular dystrophy-dystroglycanopathy congenital with mental retardation type B2 (MDDGB2) genetic test is a specialized diagnostic assessment available at DNA Labs UAE. This test is designed to identify mutations in the POMT2 gene, which are known to cause a rare form of muscular dystrophy characterized by congenital muscle weakness, structural brain anomalies, and intellectual disabilities. The condition is part of a group of disorders known as dystroglycanopathies, which affect the dystroglycan protein complex—a key component in muscle cell stability and brain development.
The test, priced at 4400 AED, involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect the presence of genetic abnormalities in the POMT2 gene. This genetic testing is crucial for early diagnosis and management of the condition, allowing for targeted interventions and support to improve the quality of life for affected individuals and their families. DNA Labs UAE, with its state-of-the-art facilities and expert team, ensures accurate and reliable testing outcomes, providing essential genetic insights for patients dealing with this challenging condition.
The POMGNT1 Gene Muscular Dystrophy-Dystroglycanopathy Congenital with Mental Retardation Type B3 genetic test is a specialized diagnostic procedure available at DNA Labs UAE. This test is designed to identify mutations in the POMGNT1 gene, which are linked to a rare form of muscular dystrophy known as dystroglycanopathy congenital with mental retardation type B3. This condition is characterized by congenital muscular dystrophy accompanied by intellectual disabilities and, in some cases, structural brain anomalies.
The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of specific genetic mutations in the POMGNT1 gene. The results of this test can provide crucial information for the diagnosis, management, and treatment planning for affected individuals and their families.
The cost of the POMGNT1 Gene Muscular Dystrophy-Dystroglycanopathy Congenital with Mental Retardation Type B3 genetic test at DNA Labs UAE is 4400 AED. This price may vary depending on additional services or consultations required. Early diagnosis through this genetic test can significantly impact the management of the condition, offering insights into potential therapies and interventions that can improve the quality of life for those affected.
The POMT2 gene plays a crucial role in the development and maintenance of muscle tissue. Mutations in this gene can lead to a specific form of muscular dystrophy known as Dystroglycanopathy, particularly the Limb-Girdle Type C2. This condition is characterized by progressive weakness and wasting of the limb muscles, among other symptoms. Early diagnosis is key to managing the symptoms and improving the quality of life for those affected.
DNA Labs UAE offers a genetic test specifically designed to detect mutations in the POMT2 gene. This test is a vital tool for diagnosing Dystroglycanopathy Limb-Girdle Type C2, enabling healthcare professionals to devise a tailored management plan for the patient. The test is conducted with a sample of the patient's DNA, usually obtained through a blood draw.
The cost of the POMT2 Gene Muscular Dystrophy-Dystroglycanopathy Limb-Girdle Type C2 Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of an accurate diagnosis cannot be overstated, as it opens the door to targeted treatments and interventions. This test is an investment in the patient's health and well-being, providing crucial information for managing this genetic condition.
The POMGNT1 gene muscular dystrophy-dystroglycanopathy limb-girdle type C3 (LGMD2O) genetic test is a specialized diagnostic procedure aimed at identifying mutations in the POMGNT1 gene, which are known to cause a specific form of muscular dystrophy. This condition is characterized by progressive weakness and wasting of the muscles around the shoulders, hips, and thighs, typically known as limb-girdle muscular dystrophy. The test is crucial for confirming the diagnosis, understanding the disease progression, and making informed decisions about treatment and management.
Performed at DNA Labs UAE, the test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the POMGNT1 gene. The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results.
By identifying the specific mutations in the POMGNT1 gene, this genetic test enables personalized treatment plans and helps in predicting the course of the disease. It also provides essential information for family planning and the assessment of the risk of passing the condition on to future generations. DNA Labs UAE offers comprehensive support and guidance throughout the testing process, ensuring patients and their families receive the necessary information and care.
The "DAG1 Gene Muscular Dystrophy-Dystroglycanopathy Limb-Girdle Type C9 Genetic Test" is a specialized diagnostic assessment performed to identify mutations in the DAG1 gene, which are associated with Limb-Girdle Muscular Dystrophy Type C9 (LGMD2I). This condition is part of a broader group of genetic disorders known as dystroglycanopathies, which affect the muscle's ability to attach to the surrounding extracellular matrix, leading to progressive muscle weakness and degeneration primarily in the shoulder and hip areas.
This genetic test is crucial for confirming a clinical diagnosis, understanding the disease's progression, and informing treatment options. It involves analyzing the patient's DNA to look for specific mutations in the DAG1 gene that are known to cause the disorder. The test is offered at DNA Labs UAE, a reputable facility equipped with advanced genetic testing technologies to ensure accurate and reliable results.
The cost of the DAG1 Gene Muscular Dystrophy-Dystroglycanopathy Limb-Girdle Type C9 Genetic Test at DNA Labs UAE is 4400 AED. This price may cover the genetic analysis, professional interpretation of the results, and a comprehensive report that can be used by healthcare providers to tailor the management and treatment plans for affected individuals. Patients considering this test are advised to consult with their healthcare providers to understand its benefits and implications fully.
The CAPN1 gene plays a crucial role in the development and maintenance of the musculoskeletal system. Mutations in the CAPN1 gene can lead to a variety of muscular and skeletal disorders, which can significantly impact an individual's quality of life. These disorders are typically characterized by muscle weakness, atrophy, and sometimes skeletal abnormalities. Early detection and diagnosis through genetic testing are essential for managing symptoms and improving outcomes.
DNA Labs UAE offers a specialized genetic test aimed at identifying mutations in the CAPN1 gene. This test is a vital tool for individuals experiencing symptoms of muscular-skeletal disorders or those with a family history of such conditions. By analyzing the genetic makeup of an individual, the test can confirm the presence of CAPN1 gene mutations, providing crucial information for diagnosis and treatment planning.
The cost of the CAPN1 related genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect any abnormalities associated with the CAPN1 gene. Results from this test can guide healthcare providers in developing personalized management plans, including physical therapy, medication, or other interventions aimed at improving patient outcomes. Early diagnosis through this genetic test can be instrumental in enhancing the quality of life for individuals affected by CAPN1 gene-related muscular-skeletal disorders.
The MUSK Gene Myasthenic Syndrome Associated with Acetylcholine Receptor Deficiency Genetic Test is a specialized diagnostic tool designed to identify mutations in the MUSK gene, which are associated with a rare form of myasthenia gravis. This condition is characterized by muscle weakness and fatigue, primarily caused by an impairment in the transmission of signals between nerves and muscles. Unlike the more common forms of myasthenia gravis that involve antibodies against the acetylcholine receptor (AChR), this syndrome involves antibodies that target the muscle-specific kinase (MuSK), leading to a reduction in AChR at the neuromuscular junction.
The test, which costs 4400 AED, is available at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. Through a detailed analysis of the patient's DNA, the test aims to identify any genetic alterations in the MUSK gene that may contribute to the development of this syndrome. The results can provide crucial information for the accurate diagnosis and tailored treatment of affected individuals, potentially improving their quality of life by managing symptoms more effectively. Given the complexity and rarity of this condition, the genetic test represents a significant step forward in the personalized medicine approach to treating neuromuscular disorders.
The SCN4A gene myasthenic syndrome is a rare genetic condition characterized by muscle weakness and fatigue. This condition is caused by mutations in the SCN4A gene, which plays a crucial role in the normal functioning of muscle cells. The SCN4A gene encodes a component of sodium channels that are essential for the transmission of electrical signals in muscle cells, facilitating muscle contraction. Mutations in this gene can disrupt the normal flow of sodium ions, leading to the symptoms associated with the syndrome.
To diagnose this condition, a specific genetic test is available that identifies mutations in the SCN4A gene. This test is crucial for confirming the diagnosis, understanding the severity of the condition, and guiding treatment decisions. The test involves collecting a DNA sample, usually through a blood draw, and analyzing the genetic material for mutations in the SCN4A gene.
In the United Arab Emirates, this genetic test is offered by DNA Labs UAE, a reputable facility known for its advanced diagnostic services. The cost of the SCN4A gene myasthenic syndrome genetic test at DNA Labs UAE is 4400 AED. This test is a valuable tool for individuals experiencing symptoms of muscle weakness and fatigue, providing them with a definitive diagnosis and enabling them to seek appropriate treatment and management strategies for their condition.
